<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Our objective was to conduct a systematic review and meta-analysis of prospective studies on <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and <z:chebi fb="27" ids="27300">vitamin D</z:chebi> intake and 25-hydroxyvitamin D status, as part of the World <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Research Fund Continuous Update Project </plain></SENT>
<SENT sid="1" pm="."><plain>We also aimed at conducting meta-analysis of <z:hpo ids='HP_0000001'>all</z:hpo> studies on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and <z:chebi fb="27" ids="27300">vitamin D</z:chebi> receptor (VDR) single-nucleotide polymorphisms </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Relevant studies were identified in PubMed (up to June 2010) </plain></SENT>
<SENT sid="3" pm="."><plain>Inclusion criteria were original and peer-reviewed publications with a prospective design (for studies on <z:chebi fb="27" ids="27300">vitamin D</z:chebi> intake or status) </plain></SENT>
<SENT sid="4" pm="."><plain>Random effects of dose-response meta-analyses were performed on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: We observed inverse associations of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> risk with dietary <z:chebi fb="27" ids="27300">vitamin D</z:chebi> [summary relative risk (RR) per 100 IU/day = 0.95, 95% CI: 0.93-0.98; 10 studies; range of intake (midpoints) = 39-719 IU/day] and serum/plasma 25-hydroxyvitamin D (RR per 100 IU/L = 0.96, 0.94-0.97; 6 studies; range = 200-1,800 IU/L), but not with total <z:chebi fb="27" ids="27300">vitamin D</z:chebi> (5 studies) </plain></SENT>
<SENT sid="6" pm="."><plain>Supplemental (2 studies; range = 0-600 IU/day) and total (4 studies; range = 79-732 IU/day) <z:chebi fb="27" ids="27300">vitamin D</z:chebi> intake and 25-hydroxyvitamin D status (6 studies; range = 200-1,800 IU/L) were inversely associated with <z:hpo ids='HP_0003003'>colon cancer</z:hpo> risk </plain></SENT>
<SENT sid="7" pm="."><plain>We did not observe statistically significant associations between FokI, PolyA, TaqI, Cdx2, and ApaI VDR polymorphisms and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> risk </plain></SENT>
<SENT sid="8" pm="."><plain>The BsmI polymorphism was associated with a lower <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> risk (RR = 0.57, 0.36-0.89 for BB versus bb, 8 studies) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: These meta-analyses support the evidence of an inverse association between <z:chebi fb="27" ids="27300">vitamin D</z:chebi> intake, 25-hydroxyvitamin D status, and the BsmI VDR polymorphism and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> risk </plain></SENT>
<SENT sid="10" pm="."><plain>IMPACT: Improving <z:chebi fb="27" ids="27300">vitamin D</z:chebi> status could be potentially beneficial against <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> incidence </plain></SENT>
</text></document>